| Year |
Title |
Altmetric |
| 2022
|
Quantitation of cystic fibrosis triple combination therapy, elexacaftor/tezacaftor/ivacaftor, in human plasma and cellular lysate
2022
|
|
| 2022
|
Routine use of low-dose glucarpidase following high-dose methotrexate in adult patients with CNS lymphoma: an open-label, multi-center phase I study.
BMC Cancer.
22.
2022
|
|
| 2022
|
Plasma and cellular ivacaftor concentrations in patients with cystic fibrosis.
Pediatric pulmonology. Supplement.
57:2745-2753.
2022
|
|
| 2022
|
Systemic Administration of a Brain Permeable Cdk5 Inhibitor Alters Neurobehavior.
Frontiers in Pharmacology.
13.
2022
|
|
| 2022
|
Pharmacokinetics, safety, tolerability, and antiviral activity of dolutegravir dispersible tablets in infants and children with HIV-1 (IMPAACT P1093): results of an open-label, phase 1–2 trial.
Lancet HIV.
9:e332-e340.
2022
|
|
| 2022
|
Time to Viral Rebound After Interruption of Modern Antiretroviral Therapies.
Clinical Infectious Diseases.
74:865-870.
2022
|
|
| 2022
|
Ivacaftor-elexacaftor-tezacaftor and tacrolimus combination in cystic fibrosis.
Journal of Cystic Fibrosis.
21:e8-e10.
2022
|
|
| 2021
|
An open-label, pilot study of veliparib and lapatinib in patients with metastatic, triple-negative breast cancer.
Breast Cancer Research.
23.
2021
|
|
| 2021
|
A Phase 1/2 Randomized, Placebo-Controlled Trial of Romidespin in Persons With HIV-1 on Suppressive Antiretroviral Therapy..
Journal of Infectious Diseases.
224:648-656.
2021
|
|
| 2021
|
A Phase 1/2 Randomized, Placebo-Controlled Trial of Romidespin in Persons with HIV-1 on Suppressive Antiretroviral Therapy.
Journal of Infectious Diseases.
224:648-656.
2021
|
|
| 2021
|
Toward Consensus on Correct Interpretation of Protein Binding in Plasma and Other Biological Matrices for COVID-19 Therapeutic Development.
Clinical Pharmacology and Therapeutics.
110:64-68.
2021
|
|
| 2021
|
Implications of Efavirenz Pharmacogenetics When Switching from Efavirenz- to Dolutegravir-containing Antiretroviral Regimens.
Clinical Infectious Diseases.
72:1820-1822.
2021
|
|
| 2021
|
Pharmacokinetics and safety of maraviroc in neonates.
AIDS.
35:419-427.
2021
|
|
| 2021
|
Pharmacokinetics and Safety of a Raltegravir-Containing Regimen in Children Aged 4 Weeks to 2 Years Living with Human Immunodeficiency Virus and Receiving Rifampin for Tuberculosis.
Journal of the Pediatric Infectious Diseases Society.
10:201-204.
2021
|
|
| 2020
|
Impact of Low Birth Weight and Prematurity on Neonatal Raltegravir Pharmacokinetics: Impaact P1097
2020
|
|
| 2020
|
Genital shedding of human immunodeficiency virus Type-1 (HIV) when antiretroviral therapy suppresses HIV replication in the plasma.
Journal of Infectious Diseases.
222:777-786.
2020
|
|
| 2020
|
Variable cellular ivacaftor concentrations in people with cystic fibrosis on modulator therapy.
Journal of Cystic Fibrosis.
19:742-745.
2020
|
|
| 2020
|
Selective Targeting of the Hedgehog Signaling Pathway by PBM Nanoparticles in Docetaxel-Resistant Prostate Cancer.
Cells.
9.
2020
|
|
| 2020
|
Raltegravir (RAL) in Neonates: Dosing, Pharmacokinetics (PK), and Safety in HIV-1-Exposed Neonates at Risk of Infection (IMPAACT P1110)
2020
|
|
| 2020
|
Antiviral therapy: Valacyclovir Treatment of Alzheimer's Disease (VALAD) Trial: Protocol for a randomised, double-blind,placebo-controlled, treatment trial.
BMJ Open.
10.
2020
|
|
| 2020
|
Advances in the development of therapeutics for cytomegalovirus infections.
Journal of Infectious Diseases.
221:32-44.
2020
|
|
| 2020
|
Long-term safety and efficacy of dolutegravir in treatment-experienced adolescents with human immunodeficiency virus infection: Results of the impaact p1093 study.
Journal of the Pediatric Infectious Diseases Society.
9:159-165.
2020
|
|
| 2019
|
Use of Modeling and Simulations to Determine Raltegravir Dosing in Neonates: A Model for Safely and Efficiently Determining Appropriate Neonatal Dosing Regimens: IMPAACT P1110
2019
|
|
| 2019
|
Pharmacokinetics and safety of a raltegravir-containing regimen in HIV-infected children aged 2-12 years on rifampicin for tuberculosis.
AIDS.
33:2197-2203.
2019
|
|
| 2019
|
Maternal–Neonatal Raltegravir Population Pharmacokinetics Modeling: Implications for Initial Neonatal Dosing
2019
|
|
| 2019
|
Antiretroviral Activity of AMD11070 (An Orally Administered CXCR4 Entry Inhibitor): Results of NIH/NIAID AIDS Clinical Trials Group Protocol A5210.
AIDS Research and Human Retroviruses.
35:691-697.
2019
|
|
| 2019
|
Dolutegravir plus lamivudine for initial treatment of HIV-1-infected participants with HIV-1 RNA <500 000 copies/mL: Week 48 outcomes from ACTG 5353.
Journal of Antimicrobial Chemotherapy.
74:1376-1380.
2019
|
|
| 2019
|
Race/ethnicity and protease inhibitor use influence plasma tenofovir exposure in adults living with HIV-1 in AIDS Clinical Trials Group Study A5202.
Antimicrobial Agents and Chemotherapy.
63.
2019
|
|
| 2019
|
Extended CCR5 Blockade for Graft-versus-Host Disease Prophylaxis Improves Outcomes of Reduced-Intensity Unrelated Donor Hematopoietic Cell Transplantation: A Phase II Clinical Trial.
Biology of Blood and Marrow Transplantation.
25:515-521.
2019
|
|
| 2019
|
Transdermal Delivery of Enfuvirtide in a Porcine Model Using a Low-Frequency, Low-Power Ultrasound Transducer Patch.
Ultrasound in Medicine and Biology.
45:513-525.
2019
|
|
| 2018
|
Safety and efficacy at 240 weeks of different raltegravir formulations in children with HIV-1: a phase 1/2 open label, non-randomised, multicentre trial.
Lancet HIV.
5:e715-e722.
2018
|
|
| 2018
|
The control of HIV after antiretroviral medication pause (CHAMP) study: Posttreatment controllers identified from 14 clinical studies.
Journal of Infectious Diseases.
218:1954-1963.
2018
|
|
| 2018
|
Randomized clinical trial to assess the impact of the broadly neutralizing HIV-1 monoclonal antibody VRC01 on HIV-1 persistence in individuals on effective ART.
Open Forum Infectious Diseases.
5.
2018
|
|
| 2018
|
HIV-1 proviral landscapes distinguish posttreatment controllers from noncontrollers.
Journal of Clinical Investigation.
128:4074-4085.
2018
|
|
| 2018
|
Monotypic low-level HIV viremias during antiretroviral therapy are associated with disproportionate production of X4 virions and systemic immune activation.
AIDS.
32:1389-1401.
2018
|
|
| 2018
|
ACTG A5353: A Pilot Study of Dolutegravir Plus Lamivudine for Initial Treatment of Human Immunodeficiency Virus-1 (HIV-1)-infected Participants with HIV-1 RNA <500000 Copies/mL.
Clinical Infectious Diseases.
66:1689-1697.
2018
|
|
| 2018
|
Dolutegravir Plus Lamivudine Maintains Human Immunodeficiency Virus-1 Suppression Through Week 48 in a Pilot Randomized Trial.
Clinical Infectious Diseases.
66:1794-1797.
2018
|
|
| 2018
|
Sensitivity of ivacaftor to drug-drug interactions with rifampin, a cytochrome P450 3A4 inducer.
Pediatric pulmonology. Supplement.
53:E6-E8.
2018
|
|
| 2018
|
Dolutegravir pharmacokinetics in pregnant and postpartum women living with HIV.
AIDS.
32:729-737.
2018
|
|
| 2018
|
Brain neurotransmitter transporter/receptor genomics and efavirenz central nervous system adverse events.
Pharmacogenetics and Genomics.
28:179-187.
2018
|
|
| 2018
|
Elvitegravir/cobicistat pharmacokinetics in pregnant and postpartum women with HIV.
AIDS.
32:2507-2516.
2018
|
|
| 2018
|
HIV RNA persists in rectal tissue despite rapid plasma virologic suppression with dolutegravir-based therapy.
AIDS.
32:2151-2159.
2018
|
|
| 2017
|
Pharmacokinetics of darunavir/ritonavir with etravirine both twice daily in human immunodeficiency virus-infected adolescents and young adults.
Journal of the Pediatric Infectious Diseases Society.
6:294-296.
2017
|
|
| 2017
|
Effective treatment of SIVcpz-induced immunodeficiency in a captive western chimpanzee.
Retrovirology.
14.
2017
|
|
| 2017
|
Clinical trial of the anti-PD-L1 antibody BMS-936559 in HIV-1 infected participants on suppressive antiretroviral therapy.
Journal of Infectious Diseases.
215:1725-1733.
2017
|
|
| 2017
|
Current status of the pharmacokinetics and pharmacodynamics of HIV-1 entry inhibitors and HIV therapy.
Current Drug Metabolism.
18:769-781.
2017
|
|
| 2017
|
Resveratrol induces cell cycle arrest and apoptosis with docetaxel in prostate cancer cells via a p53/p21WAF1/CIP1 and p27KIP1 pathway.
Oncotarget.
8:17216-17228.
2017
|
|
| 2016
|
Pharmacokinetics of unboosted atazanavir in treatment-experienced HIV-infected children, adolescents and young adults
2016
|
|
| 2016
|
Rilpivirine pharmacokinetics without and with darunavir/ritonavir once daily in adolescents and young adults
2016
|
|
| 2016
|
Pharmacokinetics of once-daily darunavir/ ritonavir with and without etravirine in human immunodeficiency virus-infected children, adolescents, and young adults.
Journal of the Pediatric Infectious Diseases Society.
5:131-137.
2016
|
|
| 2016
|
Pilot evaluation of ivacaftor for chronic bronchitis
2016
|
|
| 2016
|
Cerebrospinal fluid concentrations of tenofovir and emtricitabine in the setting of HIV-1 protease inhibitor-based regimens.
Journal of Clinical Pharmacology.
56:492-496.
2016
|
|
| 2015
|
Pharmacokinetics and 48-week safety and efficacy of raltegravir for oral suspension in human immunodeficiency virus type-1-infected children 4 weeks to 2 years of age.
Journal of the Pediatric Infectious Diseases Society.
4:e76-e83.
2015
|
|
| 2015
|
A randomized, double-blind, placebo-controlled trial of pleconaril for the treatment of neonates with enterovirus sepsis.
Journal of the Pediatric Infectious Diseases Society.
5:53-62.
2015
|
|
| 2015
|
Less Bone Loss with Maraviroc- Versus Tenofovir-Containing Antiretroviral Therapy in the AIDS Clinical Trials Group A5303 Study.
Clinical Infectious Diseases.
61:1179-1188.
2015
|
|
| 2015
|
Valganciclovir for Symptomatic Congenital Cytomegalovirus Disease.
Obstetrical and Gynecological Survey.
70:489-490.
2015
|
|
| 2015
|
Genomewide association study of tenofovir pharmacokinetics and creatinine clearance in AIDS Clinical Trials Group protocol A5202.
Pharmacogenetics and Genomics.
25:450-461.
2015
|
|
| 2015
|
Population pharmacokinetic analysis of raltegravir pediatric formulations in HIV-infected children 4 weeks to 18 years of age.
Journal of Clinical Pharmacology.
55:748-756.
2015
|
|
| 2015
|
The authors reply.
New England Journal of Medicine.
372:2463.
2015
|
|
| 2015
|
Perinatal pharmacokinetics of azithromycin for cesarean prophylaxis.
American Journal of Obstetrics and Gynecology.
212:812.e1-812.e6.
2015
|
|
| 2015
|
Valganciclovir for symptomatic congenital cytomegalovirus disease.
New England Journal of Medicine.
372:933-943.
2015
|
|
| 2015
|
Helicase-primase as a target of new therapies for herpes simplex virus infections.
Clinical Pharmacology and Therapeutics.
97:66-78.
2015
|
|
| 2015
|
Impact of protease inhibitors on intracellular concentration of tenofovir-diphosphate among HIV-1 infected patients.
AIDS.
29:1113-1115.
2015
|
|
| 2015
|
Safety, pharmacokinetics and efficacy of dolutegravir in treatment-experienced HIV-1 infected adolescents : Forty-eight-week results from IMPAACT P1093
2015
|
|
| 2014
|
Pharmacokinetic Enhancers in HIV Therapeutics.
Clinical Pharmacokinetics.
53:865-872.
2014
|
|
| 2014
|
Integrated population pharmacokinetic/viral dynamic modelling of lopinavir/ritonavir in HIV-1 treatment-Naïve patients.
Clinical Pharmacokinetics.
53:361-371.
2014
|
|
| 2014
|
Comparison of illumina and 454 deep sequencing in participants failing raltegravir-based antiretroviral therapy.
PLoS One.
9.
2014
|
|
| 2014
|
La utilización del software educativo en el desarrollo de la educación ambiental en Cuba
2014
|
|
| 2014
|
Pharmacokinetics, safety, and 48-week efficacy of oral raltegravir in HIV-1-infected children aged 2 through 18 years.
Clinical Infectious Diseases.
58:413-422.
2014
|
|
| 2014
|
A sensitive HPLC-MS/MS method for the determination of dolutegravir in human plasma
2014
|
|
| 2014
|
Effect of protein binding on unbound atazanavir and darunavir cerebrospinal fluid concentrations.
Journal of Clinical Pharmacology.
54:1063-1071.
2014
|
|
| 2014
|
Raltegravir pharmacokinetics in neonates following maternal dosing
2014
|
|
| 2014
|
Secondary metabolism pathway polymorphisms and plasma efavirenz concentrations in HIV-infected adults with CYP2B6 slow metabolizer genotypes.
Journal of Antimicrobial Chemotherapy.
69:2175-2182.
2014
|
|
| 2014
|
The posology of oseltamivir in infants with influenza infection using a population pharmacokinetic approach.
Clinical Pharmacology and Therapeutics.
96:380-389.
2014
|
|
| 2014
|
Transplacental transfer of azithromycin and its use for eradicating intra-amniotic ureaplasma infection in a primate model.
Journal of Infectious Diseases.
209:898-904.
2014
|
|
| 2013
|
Genetic and non-genetic determinants of raltegravir penetration into cerebrospinal fluid: A single arm pharmacokinetic study.
PLoS One.
8.
2013
|
|
| 2013
|
Virologic response, early HIV-1 decay, and maraviroc pharmacokinetics with the nucleos(t)ide-free regimen of maraviroc plus darunavir/ritonavir in a pilot study
2013
|
|
| 2013
|
Three distinct phases of HIV-1 RNA decay in treatment-naive patients receiving raltegravir-based antiretroviral therapy: ACTG A5248.
Journal of Infectious Diseases.
208:884-891.
2013
|
|
| 2013
|
Clinical and genetic determinants of plasma nevirapine exposure following an intrapartum dose to prevent mother-to-child HIV transmission.
Journal of Infectious Diseases.
208:662-671.
2013
|
|
| 2013
|
Neuropsychometric correlates of efavirenz pharmacokinetics and pharmacogenetics following a single oral dose.
British Journal of Clinical Pharmacology.
75:997-1006.
2013
|
|
| 2013
|
Oseltamivir pharmacokinetics, dosing, and resistance among children aged <2 years with influenza.
Journal of Infectious Diseases.
207:709-720.
2013
|
|
| 2013
|
The impact of enzyme-inducing antiepileptic drugs on antiretroviral drug levels: A case-control study.
Journal of epilepsy.
103:245-253.
2013
|
|
| 2013
|
Age-related differences in plasma and intracellular tenofovir concentrations in HIV-1-infected children, adolescents and adults.
AIDS.
27:221-225.
2013
|
|
| 2013
|
Raltegravir for HIV-1 infected children and adolescents: efficacy, safety, and pharmacokinetics..
Adolescent Health, Medicine and Therapeutics.
4:79-87.
2013
|
|
| 2013
|
Uptake of tenofovir and emtricitabine into non-monocytic female genital tract cells with and without hormonal contraceptives..
Journal of Experimental Pharmacology.
5:55-64.
2013
|
|
| 2012
|
Measurement of plasma and intracellular concentrations of raltegravir in patients with HIV infection.
AIDS.
26:2257-2259.
2012
|
|
| 2012
|
Novel method to assess antiretroviral target trough concentrations using in vitro susceptibility data.
Antimicrobial Agents and Chemotherapy.
56:5938-5945.
2012
|
|
| 2012
|
Nevirapine exposure with WHO pediatric weight band dosing: Enhanced therapeutic concentrations predicted based on extensive international pharmacokinetic experience.
Antimicrobial Agents and Chemotherapy.
56:5374-5380.
2012
|
|
| 2012
|
Oseltamivir dosing in premature infants.
Journal of Infectious Diseases.
206:847-850.
2012
|
|
| 2012
|
A highly intensified ART regimen induces long-term viral suppression and restriction of the viral reservoir in a simian AIDS model.
PLoS Pathogens.
8.
2012
|
|
| 2012
|
Acceptable plasma concentrations of raltegravir and etravirine when administered by gastrostomy tube in a patient with advanced multidrug-resistant human immunodeficiency virus infection
2012
|
|
| 2012
|
Reply to 'pharmacokinetic concerns related to darunavir/ritonavir plus raltegravir combination therapy trial'.
AIDS.
26:397-398.
2012
|
|
| 2012
|
Genome-wide association study of plasma efavirenz pharmacokinetics in AIDS Clinical Trials Group protocols implicates several CYP2B6 variants.
Pharmacogenetics and Genomics.
22:858-867.
2012
|
|
| 2012
|
Maternal azithromycin therapy for Ureaplasma intraamniotic infection delays preterm delivery and reduces fetal lung injury in a primate model.
American Journal of Obstetrics and Gynecology.
207:475.e1-475.e14.
2012
|
|
| 2012
|
Tenofovir: Once-daily dosage in the management of HIV infection
2012
|
|
| 2011
|
Efficacy of a nucleoside-sparing regimen of darunavir/ritonavir plus raltegravir in treatment-naive HIV-1-infected patients (ACTG A5262).
AIDS.
25:2113-2122.
2011
|
|
| 2011
|
Immune activation mediated change in alpha-1-acid glycoprotein: Impact on total and free lopinavir plasma exposure.
Journal of Clinical Pharmacology.
51:1539-1548.
2011
|
|
| 2011
|
Steady-state pharmacokinetics of tenofovir-based regimens in HIV-infected pediatric patients.
Antimicrobial Agents and Chemotherapy.
55:4290-4294.
2011
|
|
| 2011
|
A randomized crossover study to determine relative bioequivalence of tenofovir, emtricitabine, and efavirenz (Atripla) fixed-dose combination tablet compared with a compounded oral liquid formulation derived from the tablet
2011
|
|
| 2011
|
A dynamic Bayesian nonlinear mixed-effects model of HIV response incorporating medication adherence, drug resistance and covariates.
Annals of Applied Statistics.
5:551-577.
2011
|
|
| 2010
|
Determination of appropriate dosing of influenza drugs in pediatric patients.
Clinical Pharmacology and Therapeutics.
88:704-707.
2010
|
|
| 2010
|
Effect of CYP2B6, ABCB1, and CYP3A5 polymorphisms on efavirenz pharmacokinetics and treatment response: An AIDS clinical trials group study.
Journal of Infectious Diseases.
202:717-722.
2010
|
|
| 2010
|
Oseltamivir dosing for influenza infection in premature neonates.
Journal of Infectious Diseases.
202:563-566.
2010
|
|
| 2010
|
Hierarchical Bayesian inference for HIV dynamic differential equation models incorporating multiple treatment factors
2010
|
|
| 2010
|
Short-course raltegravir intensification does not reduce persistent low-level viremia in patients with HIV-1 suppression during receipt of combination antiretroviral therapy.
Clinical Infectious Diseases.
50:912-919.
2010
|
|
| 2010
|
A cluster-randomized trial of enhanced labor ward-based PMTCT services to increase nevirapine coverage in Lusaka, Zambia.
AIDS.
24:447-455.
2010
|
|
| 2010
|
The effect of acid reduction with a proton pump inhibitor on the pharmacokinetics of lopinavir or ritonavir in HIV-infected patients on lopinavir/ritonavir-based therapy..
Journal of Clinical Pharmacology.
50:1050-1055.
2010
|
|
| 2009
|
13C-5-FU breath test current status and future directions: A comprehensive review
2009
|
|
| 2009
|
Antiretroviral rounds. Happy 50th? Sedation for colonoscopy in HIV-infected patients..
AIDS clinical care.
21:45-46.
2009
|
|
| 2009
|
Variable Impact on Mortality of AIDS-Defining Events Diagnosed during Combination Antiretroviral Therapy: Not All AIDS-Defining Conditions Are Created Equal.
Clinical Infectious Diseases.
48:1138-1151.
2009
|
|
| 2009
|
Associations between CYP2B6 polymorphisms and pharmacokinetics after a single dose of nevirapine or efavirenz in African Americans.
Journal of Infectious Diseases.
199:872-880.
2009
|
|
| 2009
|
Hepatotoxicity and gastrointestinal intolerance when healthy volunteers taking rifampin add twice-daily atazanavir and ritonavir
2009
|
|
| 2009
|
Pharmacologic aspects of new antiretroviral drugs.
Current HIV/AIDS Reports.
6:43-50.
2009
|
|
| 2009
|
Clinical factors associated with plasma F2-isoprostane levels in HIV-infected adults.
HIV Clinical Trials.
10:181-192.
2009
|
|
| 2009
|
Electrocardiogram abnormalities with Atazanavir and Lopinavir/Ritonavir.
HIV Clinical Trials.
10:328-336.
2009
|
|
| 2009
|
Long-term impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals (ACTG 5097s).
HIV Clinical Trials.
10:343-355.
2009
|
|
| 2009
|
Novel methodology for antiretroviral quantitation in the female genital tract.
HIV Clinical Trials.
10:193-199.
2009
|
|
| 2009
|
Steady-state amprenavir, tenofovir, and emtricitabine pharmacokinetics before and after reducing ritonavir boosting of a fosamprenavir/tenofovir/ emtricitabine regimen from 200 mg to 100 mg once daily (TELEX II).
HIV Clinical Trials.
10:160-167.
2009
|
|
| 2009
|
Steady-state pharmacokinetics of lopinavir/ritonavir in combination with efavirenz in human immunodeficiency virus-infected pediatric patients
2009
|
|
| 2009
|
Zidovudine, lamivudine, and nelfinavir concentrations in amniotic fluid and maternal serum.
HIV Clinical Trials.
10:41-47.
2009
|
|
| 2008
|
No residual activity of raltegravir after development of 148 complex mutations in vivo.
Journal of the International Association of Providers of AIDS Care.
7:281-282.
2008
|
|
| 2008
|
Pharmacologic aspects of new antiretroviral drugs.
Current Infectious Disease Reports.
10:522-529.
2008
|
|
| 2008
|
Dose-response curve slope sets class-specific limits on inhibitory potential of anti-HIV drugs.
Nature Medicine.
14:762-766.
2008
|
|
| 2008
|
A sensitive HPLC-MS-MS method for the determination of raltegravir in human plasma
2008
|
|
| 2008
|
Pediatric clinical pharmacology and its implications for antiretroviral drug development.
Current Opinion in HIV and AIDS.
3:272-276.
2008
|
|
| 2008
|
Treatment response in acute/early infection versus advanced AIDS: Equivalent first and second phases of HIV RNA decline.
AIDS.
22:957-962.
2008
|
|
| 2008
|
Efavirenz-Based regimens in treatment-naive patients with a range of pretreatment HIV-1 RNA levels and CD4 cell counts.
Journal of Infectious Diseases.
197:1006-1010.
2008
|
|
| 2008
|
Fish oil and fenofibrate for the treatment of hypertriglyceridemia in HIV-infected subjects on antiretroviral therapy: Results of ACTG A5186
2008
|
|
| 2008
|
Pharmacokinetic and pharmacodynamic assessment of oral valganciclovir in the treatment of symptomatic congenital cytomegalovirus disease.
Journal of Infectious Diseases.
197:836-845.
2008
|
|
| 2008
|
Preexisting resistance to nonnucleoside reverse-transcriptase inhibitors predicts virologic failure of an efavirenz-based regimen in treatment-naive HIV-1-infected subjects.
Journal of Infectious Diseases.
197:867-870.
2008
|
|
| 2008
|
Randomized study of dual versus single ritonavir-enhanced protease inhibitors for protease inhibitor-experienced patients with HIV.
HIV Clinical Trials.
9:91-102.
2008
|
|
| 2008
|
Pharmacokinetics of an indinavir-ritonavir-fosamprenavir regimen in patients with human immunodeficiency virus
2008
|
|
| 2007
|
Cloning and characterization of recombinant rhesus macaque IL-10/Fcala-ala fusion protein: A potential adjunct for tolerance induction strategies.
Cytokine.
40:183-192.
2007
|
|
| 2007
|
Population pharmacokinetics of lamivudine in human immunodeficiency virus-exposed and -infected infants.
Antimicrobial Agents and Chemotherapy.
51:4297-4302.
2007
|
|
| 2007
|
Intracellular nucleoside triphosphate concentrations in HIV-infected patients on dual nucleoside reverse transcriptase inhibitor therapy.
Antiviral Therapy.
12:981-986.
2007
|
|
| 2007
|
Effect of concomitantly administered rifampin on the pharmacokinetics and safety of atazanavir administered twice daily.
Antimicrobial Agents and Chemotherapy.
51:3104-3110.
2007
|
|
| 2007
|
Lopinavir/ritonavir pharmacokinetic profile: Impact of sex and other covariates following a change from twice-daily to once-daily therapy.
Journal of Clinical Pharmacology.
47:970-977.
2007
|
|
| 2007
|
Persistence of nevirapine in breast milk after discontinuation of treatment.
Clinical Infectious Diseases.
45:391-394.
2007
|
|
| 2007
|
A randomized study of antiviral medication switch at lower- versus higher-switch thresholds: AIDS clinical trials group study A5115.
Antiviral Therapy.
12:531-541.
2007
|
|
| 2007
|
Development of a sensitive and specific liquid chromatography/mass spectrometry method for the determination of tenofovir in human plasma.
Rapid Communications in Mass Spectrometry.
21:2087-2094.
2007
|
|
| 2007
|
Clinical response and tolerability to and safety of saquinavir with low-dose ritonavir in human immunodeficiency virus type 1-infected mothers and their infants.
Antimicrobial Agents and Chemotherapy.
51:2208-2210.
2007
|
|
| 2007
|
Ganciclovir population pharmacokinetics in neonates following intravenous administration of ganciclovir and oral administration of a liquid valganciclovir formulation.
Clinical Pharmacology and Therapeutics.
81:867-872.
2007
|
|
| 2007
|
Pharmacokinetics of once-daily tenofovir, emtricitabine, ritonavir and fosamprenavir in HIV-infected subjects.
AIDS.
21:1373-1375.
2007
|
|
| 2007
|
Pharmacokinetic study of puerarin in rat serum by liquid chromatography tandem mass spectrometry.
Biomedical Chromatography.
21:410-414.
2007
|
|
| 2007
|
Improving data reliability using a non-compliance detection method versus using pharmacokinetic criteria.
Journal of Pharmacokinetics and Pharmacodynamics.
34:35-55.
2007
|
|
| 2007
|
Pharmacokinetics of saquinavir with atazanavir or low-dose ritonavir administered once daily (ASPIRE I) or twice daily (ASPIRE II) in seronegative volunteers.
Journal of Clinical Pharmacology.
47:201-208.
2007
|
|
| 2006
|
Design issues in initial HIV-treatment trials: Focus on ACTG A5095.
Antiviral Therapy.
11:751-760.
2006
|
|
| 2006
|
Three- vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection: A randomized controlled trial.
Journal of the American Medical Association.
296:769-781.
2006
|
|
| 2006
|
Reply to Tong et al. [4].
Clinical Infectious Diseases.
43:542-544.
2006
|
|
| 2006
|
Pharmacodynamics of antiretroviral agents in HIV-1 infected patients: Using viral dynamic models that incorporate drug susceptibility and adherence.
Journal of Pharmacokinetics and Pharmacodynamics.
33:399-419.
2006
|
|
| 2006
|
Tipranavir: A novel nonpeptidic protease inhibitor of HIV.
Clinical Pharmacokinetics.
45:665-682.
2006
|
|
| 2006
|
Clinical pharmacodynamics of HIV-1 protease inhibitors: Use of inhibitory quotients to optimise pharmacotherapy.
Lancet Infectious Diseases.
6:215-225.
2006
|
|
| 2006
|
Pharmacogenetics of plasma efavirenz exposure after treatment discontinuation: An adult AIDS clinical trials group study.
Clinical Infectious Diseases.
42:401-407.
2006
|
|
| 2006
|
Adherence-resistance relationships for protease and non-nucleoside reverse transcriptase inhibitors explained by virological fitness.
AIDS.
20:223-231.
2006
|
|
| 2006
|
Field performance of a thin-layer chromatography assay for detection of nevirapine in umbilical cord blood.
HIV Clinical Trials.
7:263-269.
2006
|
|
| 2006
|
Field performance of a thin-layer chromatography assay for detection of nevirapine in umbilical cord blood..
HIV Clinical Trials.
7:263-269.
2006
|
|
| 2005
|
Impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals.
ACP journal club.
143.
2005
|
|
| 2005
|
Four measures of antiretroviral medication adherence and virologic response in AIDS clinical trials group study 359
2005
|
|
| 2005
|
Current status and future prospects of therapeutic drug monitoring and applied clinical pharmacology in antiretroviral therapy.
Antiviral Therapy.
10:375-392.
2005
|
|
| 2005
|
Effectiveness of a city-wide program to prevent mother-to-child HIV transmission in Lusaka, Zambia.
AIDS.
19:1309-1315.
2005
|
|
| 2005
|
Therapeutic drug monitoring and drug-drug interactions involving antiretroviral drugs.
Antiviral Therapy.
10:469-477.
2005
|
|
| 2005
|
Indinavir protein-free concentrations when used in indinavir/ritonavir combination therapy.
AIDS.
19:1059-1063.
2005
|
|
| 2005
|
Modeling long-term HIV dynamics and antiretroviral response: Effects of drug potency, pharmacokinetics, adherence, and drug resistance
2005
|
|
| 2005
|
Combining fosamprenavir with lopinavir/ritonavir substantially reduces amprenavir and lopinavir exposure: ACTG protocol A5143 results.
AIDS.
19:145-152.
2005
|
|
| 2005
|
Efficacy, tolerability and pharmacokinetics of two nelfinavir-based regimens in human immunodeficiency virus-infected children and adolescents: Pediatric AIDS Clinical Trials Group Protocol 403
2005
|
|
| 2004
|
Pharmacogenetics of efavirenz and central nervous system side effects: An Adult AIDS Clinical Trials Group study.
AIDS.
18:2391-2400.
2004
|
|
| 2004
|
Comparison of two indinavir/ritonavir regimens in the treatment of HIV-infected individuals
2004
|
|
| 2004
|
Pharmacokinetics of antiretrovirals administered to HIV-infected children via gastrostomy tube.
HIV Clinical Trials.
5:288-293.
2004
|
|
| 2004
|
Weighted phenotypic susceptibility scores are predictive of the HIV-1 RNA response in protease inhibitor-experienced HIV-1-infected subjects.
Journal of Infectious Diseases.
190:886-893.
2004
|
|
| 2004
|
Pharmacokinetic enhancement of protease inhibitor therapy.
Clinical Pharmacokinetics.
43:291-310.
2004
|
|
| 2004
|
Antiretroviral drug content in products from developing countries.
Clinical Infectious Diseases.
38:1317-1319.
2004
|
|
| 2004
|
Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection.
New England Journal of Medicine.
350:1850-1861.
2004
|
|
| 2004
|
Universal nevirapine upon presentation in labor to prevent mother-to-child HIV transmission in high prevalence settings.
AIDS.
18:939-943.
2004
|
|
| 2004
|
Sex-based differences in saquinavir pharmacology and virologic response in AIDS Clinical Trials group study 359.
Journal of Infectious Diseases.
189:1176-1184.
2004
|
|
| 2004
|
Detection of Nevirapine in Plasma Using Thin-Layer Chromatography
2004
|
|
| 2004
|
Pharmacokinetics of Saquinavir plus Low-Dose Ritonavir in Human Immunodeficiency Virus-Infected Pregnant Women?.
Antimicrobial Agents and Chemotherapy.
48:430-436.
2004
|
|
| 2004
|
Effects of Concentration and Temperature on the Stability of Nevirapine in Whole Blood and Serum
2004
|
|
| 2003
|
HIV Protease Inhibitor Ritonavir Induces Lipoatrophy in Male Mice.
AIDS Research and Human Retroviruses.
19:1141-1150.
2003
|
|
| 2003
|
Duration of highly active antiretroviral therapy regimens.
Clinical Infectious Diseases.
37:714-722.
2003
|
|
| 2003
|
Monitoring nevirapine-based programmes for prevention of mother-to-child transmission of HIV-1 [4]
2003
|
|
| 2003
|
Timing of the maternal drug dose and risk of perinatal HIV transmission in the setting of intrapartum and neonatal single-dose nevirapine.
AIDS.
17:1659-1665.
2003
|
|
| 2003
|
Intermittent administration of high-dose stavudine to nucleoside-experienced individuals infected with HIV-1
2003
|
|
| 2003
|
Analysis of Generic Nevirapine Products in Developing Countries [7].
Journal of the American Medical Association.
289:2648-2649.
2003
|
|
| 2003
|
Comparison of two strategies for administering nevirapine to prevent perinatal HIV transmission in high-prevalence, resource-poor settings
2003
|
|
| 2003
|
Evaluation of multiple drug therapy in human immunodeficiency virus-infected pediatric patients
2003
|
|
| 2003
|
Evaluation of multiple drug therapy in human immunodeficiency virus-infected pediatric patients.
2003
|
|
| 2003
|
Simultaneous determination of nine antiretroviral compounds in human plasma using liquid chromatography
2003
|
|
| 2003
|
Methods for integration of pharmacokinetic and phenotypic information in the treatment of infection with human immunodeficiency virus.
Clinical Infectious Diseases.
36:373-377.
2003
|
|
| 2003
|
Therapeutic drug monitoring in the treatment of HIV-infection.
Journal of Clinical Virology.
27:117-128.
2003
|
|
| 2002
|
Single-dose pharmacokinetics of enteric-coated didanosine in HIV-infected children.
Antiviral Therapy.
7:267-270.
2002
|
|
| 2002
|
Immunologic and virologic consequences of temporary antiretroviral treatment interruption in clinical practice.
AIDS Research and Human Retroviruses.
18:909-916.
2002
|
|
| 2002
|
Effect of Seville orange juice and grapefruit juice on indinavir pharmacokinetics.
Journal of Clinical Pharmacology.
42:1165-1170.
2002
|
|
| 2002
|
Durability of response to treatment among antiretroviral-experienced subjects: 48-Week results from AIDS Clinical Trials Group Protocol 359.
Journal of Infectious Diseases.
186:626-633.
2002
|
|
| 2002
|
The pharmacokinetics of amprenavir, zidovudine, and lamivudine in the genital tracts of men infected with human immunodeficiency virus type 1 (aids clinical trials group study 850).
Journal of Infectious Diseases.
186:198-204.
2002
|
|
| 2002
|
Pharmacokinetic enhancement of protease inhibitors
2002
|
|
| 2002
|
Antiretroviral pharmacokinetics in the paediatric population: A review.
Clinical Pharmacokinetics.
41:1115-1133.
2002
|
|
| 2002
|
Position paper on therapeutic drug monitoring of antiretroviral agents.
AIDS Research and Human Retroviruses.
18:825-834.
2002
|
|
| 2001
|
Acyclovir for treatment of postherpetic neuralgia: Efficacy and pharmacokinetics.
Antimicrobial Agents and Chemotherapy.
45:2771-2774.
2001
|
|
| 2001
|
Practical implications for the interpretation of minimum plasma concentration/inhibitory concentration ratios
2001
|
|
| 2001
|
Pharmacological basis for concentration-controlled therapy with zidovudine, lamivudine, and indinavir.
Antimicrobial Agents and Chemotherapy.
45:236-242.
2001
|
|
| 2001
|
Combination therapy with indinavir, ritonavir, and delavirdine and nucleoside reverse transcriptase inhibitors in patients with HIV/AIDS who have failed multiple antiretroviral combinations.
HIV Clinical Trials.
2:193-199.
2001
|
|
| 2001
|
Indinavir, nevirapine, stavudine, and lamivudine for human immunodeficiency virus-infected, amprenavir-experienced subjects: AIDS clinical trials group protocol 373.
Journal of Infectious Diseases.
183:715-721.
2001
|
|
| 2001
|
Pharmacokinetics of saquinavir-SGC in HIV-infected pregnant women.
HIV Clinical Trials.
2:460-465.
2001
|
|
| 2000
|
Pharmacodynamics of human immunodeficiency virus type 1 protease inhibitors.
Clinical Infectious Diseases.
30.
2000
|
|
| 2000
|
Plasma population pharmacokinetics and penetration into cerebrospinal fluid of indinavir in combination with zidovudine and lamivudine in HIV-1-infected patients.
AIDS.
14:2869-2876.
2000
|
|
| 2000
|
Competing drug-drug interactions among multidrug antiretroviral regimens used in the treatment of HIV-infected subjects: ACTG 884.
AIDS.
14:2495-2501.
2000
|
|
| 2000
|
Continued lamivudine versus delavirdine in combination with indinavir and zidovudine or stavudine in lamivudine-experienced patients: Results of adult AIDS clinical trials group protocol 370.
AIDS.
14:1553-1561.
2000
|
|
| 2000
|
Long-term stability of nelfinavir mesylate in human plasma [5]
2000
|
|
| 2000
|
Phase I dose escalation pharmacokinetics of O-(chloroacetylcarbamoyl) fumagillol (TNP-470) and its metabolites in AIDS patients with Kaposi's sarcoma.
Cancer Chemotherapy and Pharmacology.
46:173-179.
2000
|
|
| 2000
|
Randomized study of saquinavir with ritonavir or nelfinavir together with delavirdine, adefovir, or both in human immunodeficiency virus-infected adults with virologic failure on indinavir: AIDS Clinical Trials Group study 359.
Journal of Infectious Diseases.
182:1375-1384.
2000
|
|
| 1999
|
Indinavir concentrations and antiviral effect
1999
|
|
| 1999
|
Pharmacokinetic strategies for concentration-targeted therapy with zidovudine (ZDV), lamivudine (3TC), and indinavir (IDV).
Clinical Pharmacology and Therapeutics.
65:161.
1999
|
|
| 1998
|
Potential confusion with antiretroviral drugs.
American Journal of Health-System Pharmacy.
55:2639-2640.
1998
|
|
| 1998
|
Concentration-controlled zidovudine therapy.
Clinical Pharmacology and Therapeutics.
64:331-338.
1998
|
|
| 1997
|
Pharmacokinetics and safety of concentration-controlled oral zidovudine therapy
1997
|
|
| 1997
|
Valacyclovir.
Annals of Pharmacotherapy.
31:185-191.
1997
|
|
| 1996
|
Clinical Pharmacokinetics of Zidovudine: An Update.
Clinical Pharmacokinetics.
30:251-262.
1996
|
|
| 1996
|
Disposition of zidovudine in obese pregnant women with human immunodeficiency virus type 1 infection [4].
Journal of Infectious Diseases.
174:673.
1996
|
|
| 1996
|
Effect of foscarnet on quantities of cytomegalovirus and human immunodeficiency virus in blood of persons with AIDS.
Antimicrobial Agents and Chemotherapy.
40:2721-2726.
1996
|
|
| 1996
|
Hepatotoxicity and rash associated with zidovudine and zalcitabine chemoprophylaxis [2].
ACP journal club.
124:855.
1996
|
|
| 1995
|
Antiretroviral drug interactions.
International Journal of Antimicrobial Agents.
5:73-83.
1995
|
|
| 1995
|
Pentamidine Concentrations in a Mother with AIDS and in Her Neonate.
Clinical Infectious Diseases.
20:1569-1570.
1995
|
|
| 1994
|
Agents for treating human immunodeficiency virus infection.
American Journal of Health-System Pharmacy.
51.
1994
|
|
| 1994
|
Gender differences in human pharmacokinetics and pharmacodynamics.
Journal of Adolescent Health.
15:619-629.
1994
|
|
| 1993
|
Advances in pharmacotherapy: treatment of HIV infection.
Journal of Clinical Pharmacy and Therapeutics.
18:375-388.
1993
|
|
| 1993
|
Leukotriene-receptor antagonists and 5-lipoxygenase inhibitors in asthma.
Annals of Pharmacotherapy.
27:898-903.
1993
|
|
| 1988
|
Thromboxane synthesis and actions in isolated adrenergic nerve (pheochromocytoma-12) cells.
Journal of Pharmacology and Experimental Therapeutics.
247:43-46.
1988
|
|
